Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.68 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913914 | 1.00 | FLT3 (0.68) | FLT3SRD5A2KMT2AKDM4EMEN1 | |
| SCHEMBL7979026 | 0.87 | FLT3 (0.68) | FLT3SRD5A2KMT2AKDM4EMEN1 | |
| SCHEMBL24447653 | 0.86 | FLT3 (0.66) | FLT3KMT2AKDM4EMEN1RCE1 | |
| SCHEMBL217459 | 0.86 | FLT3 (0.66) | FLT3KMT2AKDM4EMEN1RCE1 | |
| SCHEMBL29394458 | 0.86 | FLT3 (0.66) | FLT3KMT2AKDM4EMEN1RCE1 | |
| SCHEMBL24113092 | 0.86 | FLT3 (0.66) | FLT3SRD5A2KMT2AKDM4EMEN1 | |
| SCHEMBL30310403 | 0.86 | FLT3 (0.66) | FLT3SRD5A2KMT2AKDM4EMEN1 | |
| SCHEMBL24113353 | 0.84 | FLT3 (0.59) | FLT3SRD5A2KMT2AKDM4EMEN1 | |
| SCHEMBL24020782 | 0.83 | KMT2A (0.65) | FLT3KMT2AKDM4EMEN1RCE1 | |
| SCHEMBL1144792 | 0.83 | SRD5A2 (0.71) | FLT3SRD5A2KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2025133078-A1 | VIRAL PROTEASE INHIBITORS WITH A HYDROXYBENZYL ALCOHOL WARHEAD | STICHTING RADBOUD UNIVERSITEIT (NL) | 2025-06-26 | — | — | WO | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| US-12077605-B2 | Cysteine protease inhibitors and methods of use thereof | ANIXA BIOSCIENCES, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2024102986-A2 | SARS-COV-2 MPRO INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20230340018-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | ANIXA BIOSCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-4216961-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CORONAVIRUS INFECTION | Lighthouse Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4204393-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
| EP-4165037-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | Aligos Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| EP-4132944-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | Cocrystal Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022212707-A1 | SARS-3CL PROTEASE INHIBITORS | Primmune Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022133588-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022066776-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CORONAVIRUS INFECTION | Cortexyme, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022043374-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022040186-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | ANIXA BIOSCIENCES, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | FLT3 483/4885SRD5A2 4675/4885KMT2A 824/4885 |
| US-12077605-B2 | Cysteine protease inhibitors and methods of use thereof | SERPINB1, PREP, HPN | FLT3 3179/4885SRD5A2 3788/4885KMT2A 4385/4885 |
| US-20230340018-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | SERPINB1, PREP, PRCP | FLT3 2707/4885SRD5A2 3668/4885KMT2A 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.